Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s): CRDL

Healthcare

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

TSX:CRDL - Post by User

Cardiol Therapeutics Inc > FDA adds warning to Covivaccines on rare heart inflammation

<< Previous

Bullboard Posts

Next >>

Post by Youhillmanon Jun 24, 2021 9:59am

259 Views

Post# 33440846

FDA adds warning to Covivaccines on rare heart inflammation

A warning label will be added to the Covid vaccines, the concern is in the field that CRDL is currently doing Phase 2 & 3 trials with the FDA.

So the need to address these heart inflammation concerns is real, hopefully the FDA expedites the CRDL trials so these health concerns can be dealt with.

I'm long on CRDL!

https://www.politico.com/news/2021/06/23/fda-warning-moderna-pfizer-495717

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload